CDS2 Inhibitors

Myriocin is a potent inhibitor of serine palmitoyltransferase (SPT), the rate-limiting enzyme in sphingolipid synthesis. As CDS2 is involved in phosphatidic acid metabolism, leading to the production of diacylglycerol (DAG) for the synthesis of sphingolipids, inhibiting SPT with myriocin will decrease the substrate flow towards sphingolipid production, thereby functionally inhibiting CDS2.

Fumonisin B1 is an inhibitor of ceramide synthase, which is involved in the sphingolipid biosynthesis pathway. By inhibiting ceramide synthase, the sphingolipid synthesis is disrupted, which can reduce DAG consumption for ceramide production, indirectly leading to the functional inhibition of CDS2.

Propranolol is known to inhibit phospholipase D (PLD), which generates phosphatidic acid from phosphatidylcholine. By inhibiting PLD, propranolol reduces the availability of phosphatidic acid for CDS2 function, leading to its functional inhibition.

R59022 is a diacylglycerol kinase inhibitor. By inhibiting this kinase, R59022 can cause an accumulation of DAG, which could saturate the enzymatic activity of CDS2 and functionally inhibit its action in sphingolipid synthesis.

Triacsin C is an inhibitor of long-chain acyl-CoA synthetase. By inhibiting this enzyme, it can reduce the levels of acyl-CoA, which is necessary for the synthesis of phosphatidic acid, subsequently leading to functional inhibition of CDS2 involved in this pathway.

Perifosine inhibits the Akt signaling pathway, which is known to influence various lipid metabolic processes. Inhibition of Akt can alter the balance of lipid precursors and intermediates, potentially leading to functional inhibition of CDS2.

PDMP is an inhibitor of glucosylceramide synthase, which utilizes ceramide, a product of the CDS2 pathway. By inhibiting glucosylceramide synthase, PDMP can lead to ceramide accumulation, which may indirectly inhibit CDS2 by disrupting the flow of lipid precursors.

C75 is a fatty acid synthase inhibitor. It indirectly affects the lipid metabolism pathways that provide substrates for the synthesis of complex lipids, where CDS2 is involved, thereby functionally inhibiting CDS2.

Imipramine is known to inhibit acid sphingomyelinase, which hydrolyzes sphingomyelin to produce ceramide. Inhibition of this enzyme can lead to altered sphingomyelin and ceramide levels, potentially resulting in the functional inhibition of CDS2, which is involved in ceramide metabolism.

Tipifarnib inhibits the enzyme farnesyltransferase, affecting the prenylation and proper functioning of various signaling proteins that can influence lipid metabolism and the activity of proteins such as CDS2.